Lipum has published its Q2 report, which presents several important achievements in 2025. After successfully completing the phase I study, with results in line with expectations, the company is now preparing for a phase II study with SOL-116 in patients with rheumatoid arthritis. The company's CEO Ola Sandborgh comments:
– What feels best is of course the great results we got, which give us security and confidence to continue according to plan and advance SOL-116 into phase II. I think it looks promising to initiate the study in the first half of 2026.
Read the article at biostock.se:
Focus on preparation for Lipum during Q2 - Biostock